Last reviewed · How we verify
Higher-dose venlafaxine
Higher-dose venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability.
Higher-dose venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.
At a glance
| Generic name | Higher-dose venlafaxine |
|---|---|
| Also known as | Effexor |
| Sponsor | University of Pittsburgh |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, thereby prolonging their action at neuronal synapses. At higher doses, it also exhibits weak dopamine reuptake inhibition. This mechanism is used to treat depression and anxiety disorders by restoring neurotransmitter balance.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Social anxiety disorder
- Panic disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Somnolence
- Sexual dysfunction
- Hypertension
- Sweating
Key clinical trials
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
- Pragmatic Trial of Obsessive-compulsive Disorder (PHASE2)
- Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder (PHASE2)
- ADAPT: Addressing Depression and Pain Together (PHASE4)
- Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene (PHASE4)
- Treatment of Obsessive Compulsive Disorder in Children (PHASE3)
- Optimizing Electroconvulsive Therapy for Depression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Higher-dose venlafaxine CI brief — competitive landscape report
- Higher-dose venlafaxine updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI